Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

NECITUMUMAB for Lung squamous cell carcinoma recurrent: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 11 adverse event reports in the FDA FAERS database where NECITUMUMAB was used for Lung squamous cell carcinoma recurrent.

Most Reported Side Effects for NECITUMUMAB

Side Effect Reports % Deaths Hosp.
Platelet count decreased 68 18.5% 6 26
Malignant neoplasm progression 54 14.7% 19 16
Rash 48 13.1% 4 14
Hypomagnesaemia 46 12.5% 6 14
Neutrophil count decreased 45 12.3% 4 16
Dermatitis acneiform 44 12.0% 5 12
Febrile neutropenia 30 8.2% 3 12
Decreased appetite 29 7.9% 5 6
Neutropenia 26 7.1% 2 7
Nausea 21 5.7% 6 10
Death 20 5.5% 20 1
Anaemia 19 5.2% 1 10
Pneumonia 19 5.2% 3 11
White blood cell count decreased 18 4.9% 2 7
Skin disorder 17 4.6% 2 6

Other Indications for NECITUMUMAB

Squamous cell carcinoma of lung (122) Non-small cell lung cancer (52) Product used for unknown indication (43) Lung squamous cell carcinoma stage iv (32) Non-small cell lung cancer stage iv (25) Lung neoplasm malignant (24) Lung squamous cell carcinoma stage iii (16) Squamous cell carcinoma (10) Lung cancer metastatic (5) Lung squamous cell carcinoma metastatic (5)

Other Drugs Used for Lung squamous cell carcinoma recurrent

PEMBROLIZUMAB (36) PACLITAXEL (25) CARBOPLATIN (24) DOCETAXEL (20) RAMUCIRUMAB (18) CISPLATIN (11) GEMCITABINE (9) NIVOLUMAB (9)

Related Pages

NECITUMUMAB Full Profile All Lung squamous cell carcinoma recurrent Drugs NECITUMUMAB Demographics NECITUMUMAB Timeline